GRIA3
MOLECULAR TARGETglutamate ionotropic receptor AMPA type subunit 3
GRIA3 (glutamate ionotropic receptor AMPA type subunit 3) is targeted by 12 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting GRIA3
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | nbqx | 3.56 | 34 |
| 2 | cyclothiazide | 3.14 | 22 |
| 3 | s ampa | 3.00 | 19 |
| 4 | rs ampa | 3.00 | 19 |
| 5 | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 2.94 | 18 |
| 6 | tezampanel anhydrous | 2.71 | 14 |
| 7 | Glutamic Acid | 2.64 | 13 |
| 8 | Glutamic Acid | 2.64 | 13 |
| 9 | perampanel | 2.30 | 9 |
| 10 | bdb whuutdbjxjrkmk | 2.20 | 8 |
| 11 | aniracetam | 0.69 | 1 |
| 12 | Piracetam | 0.69 | 1 |
About GRIA3 as a Drug Target
GRIA3 (glutamate ionotropic receptor AMPA type subunit 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 12 compounds with documented GRIA3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
GRIA3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.